Future perspectives on neuroendocrine tumors

Cancer and Metastasis Reviews

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Castellano, Daniel ^a   Salazar, Ramón ^b   Raymond, Eric ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Duran i Reynals Hospital   (Spain)

^c BEAUJON HOSPITAL   (France)

Author keywords

Angiogenesis; Diagnosis; Gastroenteropancreatic neuroendocrine tumors; Genetics; Molecular markers; PROMID trial; RADIANT trials; Staging; Treatment

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLALANINE TYROSINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE LU 177; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GASTRIN; INSULIN; METHIONINE; MYC PROTEIN; OCTREOTIDE; PENTETREOTIDE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PERTUZUMAB; PROTEIN C JUN; PROTEIN P53; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; INSULINOMA; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCINTIGRAPHY; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS;

EID: 79953292452     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9294-z     Document Type: Article

References (45)

1. IM Modlin K Oberg DC Chung, et al. 2008 Gastroenteropancreatic neuroendocrine tumours The Lancet Oncology 9 1 61 72 18177818 10.1016/S1470-2045(07)70410-2 1:CAS:528:DC%2BD1cXivVOltQ%3D%3D
2. IM Modlin KD Lye M Kidd 2003 A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 4 934 959 12569593 10.1002/cncr.11105 (Pubitemid 36173145)
3. IM Modlin M Kidd I Latich, et al. 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 6 1717 1751 15887161 10.1053/j.gastro.2005.03. 038 (Pubitemid 40692562)
4. N Rashid I Modlin L Tang, et al. 1997 The proliferative status of enterochromaffin-like (ECL) cells in the gastric mucosa. The plot thickens Gastroenterology 112 Suppl 4 A644
5. MN Zikusoka M Kidd G Eick, et al. 2005 The molecular genetics of gastroenteropancreatic neuroendocrine tumors Cancer 104 11 2292 2309 16258976 10.1002/cncr.21451 1:CAS:528:DC%2BD2MXhtlWgt7nE (Pubitemid 41691550)
6. HW Yang JL Kutok NH Lee, et al. 2004 Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish Cancer Research 64 20 7256 7262 15492244 10.1158/0008-5472.CAN-04-0931 1:CAS:528:DC%2BD2cXosFynt7s%3D (Pubitemid 39372062)
7. O Nilsson B Wangberg L Johansson, et al. 1992 Praomys (Mastomys) natalensis: a model for gastric carcinoid formation The Yale Journal of Biology and Medicine 65 6 741 751 1341076 1:STN:280:DyaK2c%2FntVWjug%3D%3D Discussion 827-9 (Pubitemid 23277837)
8. R Fossmark TC Martinsen KE Bakkelund, et al. 2004 ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine Cancer Research 64 10 3687 3693 15150129 10.1158/0008-5472.CAN-03-3647 1:CAS:528:DC%2BD2cXktVWht70%3D (Pubitemid 38657949)
9. JS Crabtree PC Scacheri JM Ward, et al. 2001 A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors Proceedings of the National Academy of Sciences of the United States of America 98 3 1118 1123 11158604 10.1073/pnas.98.3.1118 1:CAS:528:DC%2BD3MXht1Smsbc%3D (Pubitemid 32121196)
10. M Kidd IM Modlin LH Tang 1998 Gastrin and the enterochromaffin-like cell: an acid update Digestive Surgery 15 3 209 217 9845587 10.1159/000018616 1:STN:280:DyaK1M%2Fmt1Whtg%3D%3D (Pubitemid 28223149)
11. D Parekh J Ishizuka CM Townsend Jr, et al. 1994 Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion Pancreas 9 1 83 90 8108375 10.1097/00006676-199401000-00013 1:STN:280:DyaK2c7ltFartg%3D%3D (Pubitemid 24007355)
12. L Kolby P Bernhardt H Ahlman, et al. 2001 A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake The American Journal of Pathology 158 2 745 755 11159212 10.1016/S0002-9440(10)64017-5 1:CAS:528:DC%2BD3MXhsFWmtbw%3D (Pubitemid 32158636)
13. LM Ellis S Samuel E Sceusi 2010 Varying opinions on the authenticity of a human midgut carcinoid cell line-letter Clinical Cancer Research 16 21 5365 5366 20959409 10.1158/1078-0432.CCR-10-2550
14. Thakker, R. V. (2006). Multiple endocrine neoplasia type I. In I. J. DeGroot & J. I. Jamesson (Eds.), Endocrinology (pp. 3509-3521). Philadelphia: Elseiver Saunders.
15. K Öberg 2005 Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment Current Opinion in Oncology 17 4 386 391 15933475 10.1097/01.cco.0000167739.56948.a9 (Pubitemid 40904429)
16. GA Kaltsas GM Besser AB Grossman 2004 The diagnosis and medical management of advanced neuroendocrine tumors Endocrine Reviews 25 3 458 511 15180952 10.1210/er.2003-0014 1:CAS:528:DC%2BD2cXlvVeltLs%3D (Pubitemid 38780668)
17. G Kloppel A Perren PU Heitz 2004 The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification Annals of the New York Academy of Sciences 1014 13 27 15153416 10.1196/annals.1294.002 (Pubitemid 38594787)
18. KP Koopmans EG de Vries IP Kema, et al. 2006 Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study The Lancet Oncology 7 9 728 734 16945767 10.1016/S1470-2045(06)70801-4 1:CAS:528: DC%2BD28Xptlyrsr4%3D (Pubitemid 44283659)
19. S Koukouraki LG Strauss V Georgoulias, et al. 2006 Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy European Journal of Nuclear Medicine and Molecular Imaging 33 4 460 466 16437218 10.1007/s00259-005-0006-1 1:CAS:528:DC%2BD28XjsFalurY%3D
20. H Orlefors A Sundin U Garske, et al. 2005 Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography The Journal of Clinical Endocrinology and Metabolism 90 6 3392 3400 15755858 10.1210/jc.2004-1938 1:CAS:528:DC%2BD2MXkvFCltrc%3D (Pubitemid 41014303)
21. M D'Onofrio G Zamboni N Faccioli, et al. 2007 Ultrasonography of the pancreas. 4. Contrast-enhanced imaging Abdominal Imaging 32 2 171 181 16838218 10.1007/s00261-006-9010-6 (Pubitemid 46883656)
22. WB Hyslop NC Balci RC Semelka 2005 Future horizons in MR imaging Magnetic Resonance Imaging Clinics of North America 13 2 211 224 15935308 10.1016/j.mric.2005.03.011 (Pubitemid 40780125)
23. SA van Tuyl JT van Noorden R Timmer, et al. 2006 Detection of small-bowel neuroendocrine tumors by video capsule endoscopy Gastrointestinal Endoscopy 64 1 66 72 16813805 10.1016/j.gie.2006.01.054 (Pubitemid 43949383)
24. T Yamaguchi N Manabe S Tanaka, et al. 2005 Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique Gastrointestinal Endoscopy 62 2 315 318 16047008 10.1016/S0016- 5107(05)01569-5 (Pubitemid 41021571)
25. G Rindi G Kloppel H Alhman, et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Archiv 449 4 395 401 16967267 10.1007/s00428-006-0250-1 1:STN:280:DC%2BD28rmtlGntA%3D%3D (Pubitemid 44451313)
26. G Rindi G Kloppel A Couvelard, et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Archiv 451 4 757 762 17674042 10.1007/s00428-007-0452-1 1:STN:280:DC%2BD2srnsVyjsw%3D%3D (Pubitemid 47497934)
27. K Öberg L Kvols M Caplin, et al. 2004 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Annals of Oncology 15 6 966 973 15151956 10.1093/annonc/mdh216 (Pubitemid 39004355)
28. K Öberg S Jelic 2009 Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up Annals of Oncology 20 Suppl 4 150 153 19454440
29. SA Benjegard E Forssell-Aronsson B Wangberg, et al. 2001 Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector European Journal of Nuclear Medicine 28 10 1456 1462 11685487 10.1007/s002590100600 1:CAS:528:DC%2BD3MXmvFSluro%3D
30. A Rinke HH Muller C Schade-Brittinger, et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group Journal of Clinical Oncology 27 28 4656 4663 19704057 10.1200/JCO.2009.22.8510 1:CAS:528:DC%2BD1MXhtlGgtbnJ
31. H Shojamanesh F Gibril A Louie, et al. 2002 Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma Cancer 94 2 331 343 11900219 10.1002/cncr.10195 1:CAS:528:DC%2BD38XhtV2qsr0%3D (Pubitemid 34081361)
32. F Panzuto M Di Fonzo E Iannicelli, et al. 2006 Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma Annals of Oncology 17 3 461 466 16364959 10.1093/annonc/mdj113 1:STN:280:DC%2BD287ht1Orsw%3D%3D (Pubitemid 43329584)
33. L Kolby G Persson S Franzen, et al. 2003 Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours The British Journal of Surgery 90 6 687 693 12808615 10.1002/bjs.4149 1:STN:280:DC%2BD3s3otVCrsg%3D%3D (Pubitemid 36760596)
34. MA Kouvaraki JA Ajani P Hoff, et al. 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas Journal of Clinical Oncology 22 23 4762 4771 15570077 10.1200/JCO.2004.04.024 1:CAS:528:DC%2BD2MXhtFKq (Pubitemid 41185087)
35. DE Hansel A Rahman J Hermans, et al. 2003 Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression Modern Pathology 16 7 652 659 12861060 10.1097/01.MP.0000077416. 68489.50 (Pubitemid 36871497)
36. ML Fjällskog O Hessman B Eriksson, et al. 2007 Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas Acta Oncológica 46 6 741 746 17653895 10.1080/02841860601048388 (Pubitemid 47123755)
37. ML Fjällskog MH Lejonklou KE Oberg, et al. 2003 Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clinical Cancer Research 9 4 1469 1473 12684421 (Pubitemid 36418403)
38. P Niccoli J Raoul Y Bang, et al. 2010 Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET) Journal of Clinical Oncology 28 Suppl 15 4000 Meeting abstracts
39. Pavel, M.; Hainsworth, J.D.; Baudin, E.; et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus plus octreotide LAR vs ersus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). In: 35th European Medical Oncology Society; 2010; Milan, Italy.
40. Yao, J.C.; Shah, M.H.; Ito, T.; et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). In: 35th European Society Medical Oncology; 2010; Milan, Italy.
41. TJ Hobday J Rubin K Holen, et al. 2007 MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study Journal of Clinical Oncology 25 Suppl 18 4504 Meeting abstracts
42. Castellano, D.; Capdevilla, J.; Salazar, R.; et al. (2010). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801). In: 35th European Society of Medical Oncology; 2010; Milan, Italy.
43. F Forrer R Valkema DJ Kwekkeboom, et al. 2007 Neuroendocrine tumors. Peptide receptor radionuclide therapy Best Practice & Research. Clinical Endocrinology & Metabolism 21 1 111 129 10.1016/j.beem.2007.01.007 1:CAS:528:DC%2BD2sXjsVSqtr4%3D (Pubitemid 46421906)
44. DJ Kwekkeboom WW de Herder BL Kam, et al. 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology 26 13 2124 2130 18445841 10.1200/JCO.2007.15.2553 1:CAS:528:DC%2BD1cXms1Ort7s%3D
45. M van Essen EP Krenning BL Kam, et al. 2008 Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging 35 4 743 748 18188559 10.1007/s00259-007-0688-7